Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Antonella Tosco, Valeria R. Villella, Alice Castaldo, Guido Kroemer, Luigi Maiuri & Valeria Raia. (2018) Repurposing therapies for the personalised treatment of cystic fibrosis. Expert Opinion on Orphan Drugs 6:6, pages 361-373.
Read now
Read now
Zhi-Shuai Hou, Alfredo Ulloa-Aguirre & Ya-Xiong Tao. (2018) Pharmacoperone drugs: targeting misfolded proteins causing lysosomal storage-, ion channels-, and G protein-coupled receptors-associated conformational disorders. Expert Review of Clinical Pharmacology 11:6, pages 611-624.
Read now
Read now
Marilyn N. Bulloch, Cameron Hanna & Richard Giovane. (2017) Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation. Expert Review of Clinical Pharmacology 10:10, pages 1055-1072.
Read now
Read now
Articles from other publishers (16)
Shogo Taniguchi, Ryosuke Fukuda & Tsukasa Okiyoneda. (2023) The multiple ubiquitination mechanisms in CFTR peripheral quality control. Biochemical Society Transactions.
Crossref
Crossref
Rasa Ruseckaite, Farhad Salimi, Arul Earnest, Scott C. Bell, Tonia Douglas, Katherine Frayman, Lucy Keatley, Susannah King, Tom Kotsimbos, Peter G. Middleton, Sue Morey, Siobhain Mulrennan, Andre Schultz, Claire Wainwright, Nathan Ward, Peter Wark & Susannah Ahern. (2022) Survival of people with cystic fibrosis in Australia. Scientific Reports 12:1.
Crossref
Crossref
Erica Franceschinis, Marco Roverso, Daniela Gabbia, Sara De Martin, Matteo Brusegan, Christian Vaccarin, Sara Bogialli & Adriana Chilin. (2022) Self-Emulsifying Formulations to Increase the Oral Bioavailability of 4,6,4′-Trimethylangelicin as a Possible Treatment for Cystic Fibrosis. Pharmaceutics 14:9, pages 1806.
Crossref
Crossref
Katerina Manika & Filia Diamantea. (2022) The new triple combination in CFTR modulators: A new era in the management of cystic fibrosis. Pneumon 35:2, pages 1-4.
Crossref
Crossref
Darren Le GrandMartin GoslingUrs BaettigParmjit BahraKamlesh BalaCara Brocklehurst, Emma BuddRebecca ButlerAtwood K. Cheung, Hedaythul ChoudhuryStephen P. CollingwoodBrian Cox, Henry DanahayLee Edwards, Brian EverattUlrike Glaenzel, Anne-Lise GlotinPaul Groot-Kormelink, Edward Hall, Julia HattoCatherine HowshamGlyn HughesAnna KingJulia Koehler, Swarupa Kulkarni, Megan LightfootIan Nicholls, Christopher PageGiles Pergl-WilsonMariana Oana PopaRichard Robinson, David Rowlands, Tom SharpMatthew SpendiffEmily StanleyOliver StewardRoger J. TaylorPamela TranterTrixie Wagner, Hazel WatsonGareth Williams, Penny WrightAlice YoungDavid A. Sandham. (2021) Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease. Journal of Medicinal Chemistry 64:11, pages 7241-7260.
Crossref
Crossref
Angela Chen, Elleana J. Majdinasab, Mariana C. Fiori, Hongjun Liang & Guillermo A. Altenberg. (2020) Polymer-Encased Nanodiscs and Polymer Nanodiscs: New Platforms for Membrane Protein Research and Applications. Frontiers in Bioengineering and Biotechnology 8.
Crossref
Crossref
Fahad A. Almughem, Ahmad M. Aldossary, Essam A. Tawfik, Mohammad N. Alomary, Waleed S. Alharbi, Mohammad Y. Alshahrani & Abdullah A. Alshehri. (2020) Cystic Fibrosis: Overview of the Current Development Trends and Innovative Therapeutic Strategies. Pharmaceutics 12:7, pages 616.
Crossref
Crossref
Antonella Tosco, Valeria R. Villella, Valeria Raia, Guido Kroemer & Luigi Maiuri. (2020) Cystic Fibrosis: New Insights into Therapeutic Approaches. Current Respiratory Medicine Reviews 15:3, pages 174-186.
Crossref
Crossref
Valeria R. Villella, Antonella Tosco, Speranza Esposito, Gianni Bona, Valeria Raia & Luigi Maiuri. (2019) Mutation-specific therapies and drug repositioning in cystic fibrosis. Minerva Pediatrica 71:3.
Crossref
Crossref
Iwona Pranke, Anita Golec, Alexandre Hinzpeter, Aleksander Edelman & Isabelle Sermet-Gaudelus. (2019) Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine. Frontiers in Pharmacology 10.
Crossref
Crossref
Meraj A. Khan, Zubair Sabz Ali, Neil Sweezey, Hartmut Grasemann & Nades Palaniyar. (2019) Progression of Cystic Fibrosis Lung Disease from Childhood to Adulthood: Neutrophils, Neutrophil Extracellular Trap (NET) Formation, and NET Degradation. Genes 10:3, pages 183.
Crossref
Crossref
Elpis Hatziagorou, Eleana Kouroukli, Vasiliki Georgopoulou & John Tsanakas. (2018) A Case Report of Pulmonary Exacerbation after Initiation of Lumacaftor/Ivacaftor Therapy in a CF Female with Complicated Lung Disease. Case Reports in Pulmonology 2018, pages 1-3.
Crossref
Crossref
Steven E. Van der Plas, Hans Kelgtermans, Tom De Munck, Sébastien L. X. Martina, Sébastien Dropsit, Evelyne Quinton, Ann De Blieck, Caroline Joannesse, Linda Tomaskovic, Mia Jans, Thierry Christophe, Ellen van der Aar, Monica Borgonovi, Luc Nelles, Maarten Gees, Pieter Stouten, Jan Van Der Schueren, Oscar Mammoliti, Katja Conrath & Martin Andrews. (2018)
Discovery of
N
-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4
H
-thieno[2,3-
c
]pyran-2-yl)-l
H
-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High Extent
. Journal of Medicinal Chemistry 61:4, pages 1425-1435.
Crossref
Crossref
Dan Lindholm, Laura Korhonen, Ove Eriksson & Sulev Kõks. (2017) Recent Insights into the Role of Unfolded Protein Response in ER Stress in Health and Disease. Frontiers in Cell and Developmental Biology 5.
Crossref
Crossref
Sujin Lee, Puay-Wah Phuan, Christian M. Felix, Joseph-Anthony Tan, Marc H. Levin & Alan S. Verkman. (2017) Nanomolar-Potency Aminophenyl-1,3,5-triazine Activators of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Channel for Prosecretory Therapy of Dry Eye Diseases. Journal of Medicinal Chemistry 60:3, pages 1210-1218.
Crossref
Crossref
Giusy Ranucci, Roman Polishchuck & Raffaele Iorio. (2017) Wilson’s disease: Prospective developments towards new therapies. World Journal of Gastroenterology 23:30, pages 5451.
Crossref
Crossref